Oramed Pharmaceuticals Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $181.8M
- Price
- $4.37
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.23%
- Volume
- 84.8K
About
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Quick stats
Shares outstanding41.6M
Computed float33.3M
Float / shares80.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001176309
Websitehttps://www.oramed.com
AI Summary
AI-generated1/6
standardbullishboard change
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
Nano Dimension appointed Nadav Kidron, CEO of Oramed Pharmaceuticals and a significant shareholder, to its Board of Directors.
Kidron will chair a newly established Strategy and Capital Allocation Committee focused on monetizing non-core assets and potentially returning capital to shareholders.
The Board views this as a step to simplify the company and maximize long-term value using its substantial financial resources.